SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Qfitlia

SNY·Sanofi
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in the US (since March 2025), China (since Dec 2025), and India (since Oct 2026).
Why 4/10
Qfitlia is already FDA-approved and commercially launched in the US, with no pending PDUFA or pivotal readout in the next ~12 months; additional country approvals (e.g., EMA) are possible but not hard-dated. As a small part of Sanofi's massive diversified pipeline, even a major commercial surprise would not drive a large share-price move.
Actionable Insight NEUTRAL

Qfitlia is already approved in the US (March 2025), China (Dec 2025), and India (Oct 2026). The next catalysts to watch are potential European Medicines Agency (EMA) approval and additional country-level launches, though no hard dates are publicly set. Commercial adoption and payer uptake in the US will determine whether the drug reaches its projected $500M-$1.5B peak sales range, but for Sanofi this is a modest contributor within a $50B+ revenue base.

Price Chart

Loading chart...

Executive Summary

Qfitlia (fitusiran) is a first-in-class RNAi therapy approved by the FDA in March 2025 for routine prophylaxis of bleeding in hemophilia A and B patients aged 12 and older, with or without inhibitors. Developed by Sanofi (SNY) in partnership with Alnylam, it is the only antithrombin-lowering therapy for hemophilia and offers subcutaneous dosing as infrequently as once every two months. Phase 3 ATLAS trials showed a 71-90% reduction in annualized bleeding rates versus on-demand therapy. The drug carries a boxed warning for thrombosis and gallbladder disease. Additional approvals have been secured in China (Dec 2025) and India (Oct 2026). For Sanofi, a $105B market-cap diversified pharma giant, Qfitlia is a modest contributor with projected peak sales of $500M-$1.5B, facing entrenched competition from Roche's Hemlibra and other non-factor therapies.

How It Works

Qfitlia is a small interfering RNA (siRNA) drug that works by blocking the production of a protein called antithrombin, which normally acts as a natural brake on blood clotting. By lowering antithrombin levels, the drug shifts the patient's coagulation system toward a more clot-friendly state, compensating for the missing clotting factor that causes hemophilia. It is given as a shot under the skin once every two months.

Trial Status

Qfitlia was approved by the FDA on March 28, 2025, based on the Phase 3 ATLAS clinical program (ATLAS-INH, ATLAS-A/B, and ATLAS-OLE). The ATLAS-OLE open-label extension study (NCT03754790) is ongoing, evaluating the antithrombin-based dose regimen targeting AT levels of 15-35%. Published data showed fitusiran reduced annualized bleeding rates by approximately 71-73% versus on-demand therapy in patients without and with inhibitors, respectively, and by up to 90% versus on-demand bypassing agents.

The Two-Sided Case

▲ Bull Case5
Qfitlia is the first and only FDA-approved antithrombin-lowering therapy for hemophilia, offering a novel RNAi mechanism that works for both hemophilia A and B, with or without inhibitors, a broader label than most competitors.
Dosing is just once every two months (as few as 6 injections per year) via subcutaneous injection, a significant convenience advantage over older therapies requiring frequent IV infusions.
Phase 3 ATLAS trials demonstrated a 71-73% reduction in annualized bleeding rate versus on-demand therapy, and up to 90% reduction versus on-demand bypassing agents in inhibitor patients.
Early payer response has been positive, and the drug is now available through specialty infusion networks in the US, with additional approvals in China and India expanding the addressable market.
Sanofi is a massive, diversified global pharma company ($105B market cap) with the commercial infrastructure to launch Qfitlia across multiple geographies without strain.
▼ Bear Case5
Qfitlia carries an FDA boxed warning for thrombotic events and gallbladder disease, requiring mandatory antithrombin monitoring that may limit adoption versus competitors without such requirements.
The hemophilia market is increasingly crowded: Roche's Hemlibra (emicizumab) is the entrenched market leader, and Pfizer's Hympavzi and Novo Nordisk's Alhemo are competing for the same non-factor prophylaxis space.
At a ~$642,000/year list price, Qfitlia faces payer pushback and rebate pressure, and Sanofi expects actual net prices to be significantly lower after discounts.
Projected peak sales of $500M-$1.5B are modest relative to Sanofi's $13.4B quarterly revenue, meaning Qfitlia is unlikely to be a needle-moving catalyst for the stock.
Multiple analyst downgrades (UBS, Barclays, Guggenheim, JP Morgan) in late 2025/early 2026 reflect broader concerns about Sanofi's growth trajectory beyond Dupixent.

Upcoming Catalysts

  • Potential European Medicines Agency (EMA) approval decision, though no date has been publicly set.
  • Additional country-level approvals and launches (e.g., Japan, other Asia-Pacific markets).
  • Ongoing ATLAS-OLE long-term safety and efficacy data readouts at medical conferences.
  • Quarterly commercial sales updates in Sanofi earnings reports, providing early adoption signals.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 14

Hover a chip for the title
1 prnewswire.com2 fiercepharma.com3 businesswire.com4 ainvest.com5 managedhealthcareexecutive.com6 pharmacytimes.com7 expresspharma.in8 thepharmaletter.com9 nasdaq.com10 site.financialmodelingprep.com11 peptrackerpro.com12 sanofi.com13 go.drugbank.com14 trialfriend.com